Results for "** diabetes"
Diabetes Mellitus
** Diabetes mellitus is a chronic endocrine disorder marked by persistently elevated blood glucose due to insufficient insulin production, insulin resistance, or both, leading to systemic complications if not properly managed. **CONTENT:** ## Overview Diabetes mellitus, often simply called **diabetes**, comprises a group of metabolic diseases in which the body cannot maintain normal glucose homeostasis. Glucose is the primary fuel for cells, and its regulation depends on the hormone **insulin**, secreted by the pancreatic β‑cells. In **type 1 diabetes**, an autoimmune attack destroys these β‑cells, resulting in little or no insulin. In **type 2 diabetes**, the majority of cases worldwide, the pancreas initially produces insulin but peripheral tissues become **insulin‑resistant**, forcing the organ to work harder until it eventually fails. A third, less common form—**gestational diabetes**—arises during pregnancy and usually resolves after delivery, though it raises future risk for both mother and child. Classic clinical features are the “three Ps”: **polydipsia** (excessive thirst), **polyuria** (frequent urination), and **polyphagia** (increased hunger), often accompanied by unintentional **weight loss**, blurred vision, and fatigue. Diagnosis relies on laboratory criteria such as fasting plasma glucose ≥126 mg/dL, a 2‑hour oral glucose tolerance test ≥200 mg/dL, or an HbA1c ≥6.5 %. If left untreated, chronic hyperglycemia damages blood vessels and nerves, precipitating a spectrum of **microvascular** (retinopathy, nephropathy, neuropathy) and **macrovascular** (coronary artery disease, stroke, peripheral arterial disease) complications. These sequelae account for the disease’s high mortality: roughly **4.2 million deaths** per year worldwide, with about **1.5 million** directly attributable to untreated or poorly controlled diabetes. Early detection, lifestyle modification, and individualized pharmacotherapy are essential to prevent or delay these outcomes. **Anyone experiencing persistent symptoms or at high risk (e.g., family history, obesity, sedentary lifestyle) should seek professional medical evaluation promptly.** ## History/Background The earliest written record of diabetes dates to an Egyptian papyrus (c. 1500 BC) describing “excessive urination.” The term “diabetes” (Greek for “siphon”) was coined by the physician **Aretaeus of Cappadocia** in the 2nd century AD, while **Madhava** of India noted the sweet taste of urine in the 6th century. In 1869, **Paul Langerhans** identified the pancreatic islets (now called **Langerhans islets**) that later proved to be the source of insulin. The breakthrough came in 1921–1922 when **Frederick Banting**, **Charles Best**, and **John Macleod** isolated insulin, enabling life‑saving therapy for type 1 diabetes. The mid‑20th century saw the rise of **type 2 diabetes** as a public health issue, linked to urbanization, dietary changes, and obesity. The **World Health Organization** (WHO) officially recognized diabetes as a global epidemic in the 1990s, prompting the first **International Diabetes Federation (IDF)** conference in 1999. Since then, diagnostic criteria have been refined (e.g., introduction of HbA1c as a diagnostic test in 2010) and novel drug classes—**metformin**, **GLP‑1 receptor agonists**, **SGLT2 inhibitors**—have expanded therapeutic options. ## Key Information - **Classification:** Type 1, Type 2, Gestational, and specific monogenic forms (MODY, neonatal diabetes). - **Epidemiology:** Over 537 million adults (≈ 10 % of the global population) live with diabetes; prevalence is rising fastest in low‑ and middle‑income countries. - **Pathophysiology:** - *Insulin deficiency*: autoimmune β‑cell destruction (type 1) or β‑cell exhaustion (type 2). - *Insulin resistance*: impaired signaling in muscle, adipose, and hepatic tissue, often driven by excess adiposity and inflammatory cytokines. - **Diagnostic thresholds:** Fasting glucose ≥126 mg/dL, 2‑hour OGTT ≥200 mg/dL, HbA1c ≥6.5 %, or random glucose ≥200 mg/dL with classic symptoms. - **Management pillars:** 1. **Lifestyle:** balanced diet (Mediterranean or DASH patterns), regular aerobic and resistance exercise, weight control. 2. **Pharmacotherapy:** metformin first‑line for type 2; insulin for type 1 and advanced type 2; adjunct agents (SGLT2 inhibitors, GLP‑1 agonists) for cardiovascular/renal protection. 3. **Monitoring:** self‑monitoring of blood glucose (SMBG), periodic HbA1c, blood pressure, lipid profile, and screening for complications (annual retinal exam, urine albumin, foot exam). - **Complications:** - *Microvascular*: diabetic retinopathy (leading cause of blindness), diabetic nephropathy (major cause of end‑stage renal disease), peripheral neuropathy (risk of foot ulcers). - *Macrovascular*: accelerated atherosclerosis, increased risk of myocardial infarction and stroke. - **Prevention:** Primary prevention focuses on obesity reduction, physical activity, and dietary quality; secondary prevention emphasizes early detection and tight glycemic control. ## Significance Diabetes mellitus is a **public health priority** because it intersects with virtually every organ system and amplifies the burden of cardiovascular disease, the leading cause of death worldwide. Economically, the disease imposes staggering costs—estimated at **US $966 billion** in 2021—through direct medical expenses and lost productivity. The advent of newer drug classes that confer **cardiorenal protection** has reshaped treatment algorithms, underscoring the importance of a **multidisciplinary approach** involving endocrinologists, primary care physicians, dietitians, diabetes educators, and mental‑health professionals. Beyond the clinical realm, diabetes drives research innovation: **continuous glucose monitoring (CGM)**, **automated insulin delivery (“artificial pancreas”)**, and **gene‑editing therapies** for monogenic forms are rapidly moving from bench to bedside. Public‑health initiatives such as the WHO’s **Global Diabetes Compact** aim to halve premature deaths from diabetes by 2030, emphasizing early screening, equitable access to medicines, and health‑promoting policies. **For anyone suspecting diabetes or managing the condition, regular follow‑up with a qualified health professional is essential** to tailor therapy, monitor for complications, and adjust lifestyle measures. Early, evidence‑based intervention can dramatically improve quality of life and longevity. **INFOBOX:** - Name: Diabetes mellitus - Type: Chronic endocrine/metabolic disorder - Date: First clinical description c. 1500 BC; modern insulin therapy 1922 - Location: Worldwide (global prevalence) - Known For: Persistent hyperglycemia, insulin deficiency or resistance, and systemic complications **TAGS:** diabetes, insulin, hyperglycemia, type 1 diabetes, type 2 diabetes, metabolic disease, chronic illness, public health
Health & MedicineDiabetes Type 2
** Type 2 diabetes mellitus is a chronic metabolic disorder characterized by insulin resistance and relative insulin deficiency, leading to elevated blood glucose levels. **CONTENT:** ## Overview **Type 2 diabetes mellitus (T2DM)** is the most common form of diabetes, accounting for roughly 90‑95 % of all cases worldwide. It develops when the body’s cells become less responsive to insulin—a hormone produced by the pancreas that facilitates glucose uptake—and the pancreas cannot produce enough insulin to overcome this resistance. The resulting hyperglycemia (high blood sugar) can damage blood vessels, nerves, and organs over time, increasing the risk of cardiovascular disease, kidney failure, vision loss, and peripheral neuropathy. Risk factors are multifactorial and include **genetic predisposition**, excess body weight (particularly abdominal adiposity), physical inactivity, advancing age, and certain ethnic backgrounds (e.g., South Asian, African‑American, Hispanic). Lifestyle modifications such as weight loss, regular aerobic exercise, and a balanced diet rich in fiber and low in refined sugars are first‑line strategies for prevention and early management. Pharmacologic therapy—most commonly metformin, followed by additional oral agents or injectable GLP‑1 receptor agonists and insulin—may be required when lifestyle changes alone cannot achieve glycemic targets. Because T2DM is progressive, regular monitoring of **HbA1c**, blood pressure, lipid profiles, and renal function is essential. Patients should seek professional medical care promptly if they experience symptoms such as unexplained weight loss, persistent thirst, frequent urination, blurred vision, or signs of infection, as early intervention can prevent complications. ## History/Background The clinical picture of diabetes has been recognized for millennia, with descriptions in ancient Egyptian papyri (≈1500 BC) and Ayurvedic texts. However, the distinction between insulin‑dependent (type 1) and non‑insulin‑dependent (type 2) forms emerged only in the 20th century. In 1936, **Elliott Joslin** and colleagues noted a “milder” form of diabetes that responded poorly to insulin, coining the term “adult‑onset diabetes.” The discovery of insulin in 1921 and subsequent epidemiologic studies after World War II revealed a rising prevalence linked to urbanization and dietary changes. By the 1970s, the **Oral Glucose Tolerance Test (OGTT)** became a standard diagnostic tool, and the **World Health Organization (WHO)** formally defined T2DM criteria in 1980. The epidemic accelerated in the 1990s with the global spread of obesity, prompting the **International Diabetes Federation (IDF)** to launch worldwide awareness campaigns and research initiatives. ## Key Information - **Pathophysiology:** Central features are **insulin resistance** in muscle and liver tissue and progressive **β‑cell dysfunction** in the pancreas. Chronic low‑grade inflammation, ectopic fat deposition, and altered gut microbiota contribute to disease progression. - **Diagnostic criteria (2023 ADA):** Fasting plasma glucose ≥ 126 mg/dL (7.0 mmol/L), 2‑hour OGTT glucose ≥ 200 mg/dL (11.1 mmol/L), HbA1c ≥ 6.5 % (48 mmol/mol), or a random plasma glucose ≥ 200 mg/dL with classic symptoms. - **Management hierarchy:** 1) Lifestyle intervention (5‑10 % weight loss, ≥150 min/week moderate activity); 2) Metformin as first‑line pharmacotherapy; 3) Additional agents (SGLT2 inhibitors, GLP‑1 agonists) chosen based on comorbidities; 4) Insulin when glycemic targets remain unmet. - **Complications:** Macrovascular (coronary artery disease, stroke, peripheral arterial disease) and microvascular (diabetic retinopathy, nephropathy, neuropathy). Early detection of albuminuria and retinal changes is vital. - **Epidemiology:** As of 2022, over 537 million adults live with diabetes globally; > 90 % have T2DM. Prevalence is highest in the Western Pacific and Southeast Asian regions, reflecting rapid lifestyle transitions. - **Prevention:** The **Diabetes Prevention Program (DPP)** demonstrated a 58 % risk reduction through modest weight loss and increased physical activity, underscoring the power of behavioral change. ## Significance T2DM represents a major public‑health challenge due to its high prevalence, chronic nature, and costly complications. Economically, diabetes care consumes an estimated 10‑15 % of national health expenditures in many high‑income countries, straining healthcare systems. Socially, the disease disproportionately affects disadvantaged populations, amplifying health inequities. Advances in pharmacotherapy—particularly SGLT2 inhibitors and GLP‑1 receptor agonists—have shifted the therapeutic paradigm from glucose‑centric to **cardiorenal‑protective** strategies, reducing mortality and hospitalizations. Moreover, emerging research on genetics, precision nutrition, and digital health tools (continuous glucose monitors, telemedicine) promises more personalized and proactive disease management. Public‑policy initiatives, such as sugar‑taxes and urban planning that encourages active transport, aim to curb the upstream drivers of obesity and insulin resistance, highlighting the societal importance of addressing T2DM holistically. **When to seek professional care:** Anyone experiencing classic diabetes symptoms, unexplained weight loss, or persistent hyperglycemia should consult a healthcare provider promptly. Even individuals without symptoms but with risk factors (family history, obesity, gestational diabetes) should undergo screening, as early diagnosis enables interventions that can delay or prevent complications. **INFOBOX:** - Name: Type 2 Diabetes Mellitus - Type: Chronic metabolic disease - Date: First distinguished as “adult‑onset diabetes” in 1936 - Location: Worldwide (global prevalence) - Known For: Being the most common form of diabetes and a leading cause of preventable morbidity and mortality **TAGS:** diabetes, type 2, insulin resistance, metabolic syndrome, chronic disease, public health, obesity, glucose monitoring